Myto Health to attend Partnering at BIO International Convention 2023
MALVERN, PA., May 25, 2023 — Myto Health LLC., a Biotech devoted to improving mitochondrial health, discovering nutraceuticals and pharmaceuticals to alleviate neurodegeneration and chronic diseases of aging will be attending Bio International Convention to be health in Boston June 5-8, 2023. Bio International Convention is the largest gathering of pharma and biotech companies in the world. Myto Health will share its science and technology platform with collaborators and investors. Myto Health has established a small molecule screening platform, and discovered molecules from natural product libraries that target damaged mitochondria, promote repair, and regenerate new mitochondria. These natural products are generally safe, and potential to have a major impact on human health without approval from FDA (nutraceuticals). Myto Health has identified small molecule that target mitochondria to improve Parkinson’s disease functions in cellular and animal models. Company’s science on the study neurodegeneration will help in the development of nutraceuticals, pharmaceuticals, and blood-based biomarkers for aging. We look forward to sharing these platforms during our one-on-one biopartnering meetings at BIO.
Dates: June 5-8, 2023
Location: Boston Convention & Exhibition Center, Boston, MA
Delegate: Dr. Tauseef Butt, Principal Myto Health LLC
For more information regarding BIO 2023, explore their website BIO Events | BIO .
About Myto Health LLC. Located in Malvern PA, Great Valley Corporate Center, Myto Health LLC, is a biotech company focused on Improving mitochondrial health and its impact on aging and chronic diseases. Mitochondrial dysfunction is the root cause of many chronic diseases and aging. Enhancing mitochondrial function by small molecules or natural products induces new mitochondrial biogenesis, overcome disease, restore neuronal and muscle cells to elevate many chronic diseases such as memory, cognition, muscle function, and metabolic diseases. Study of neurodegeneration such as Alzheimer’s and Parkinson’s disease will help the company in development of nutraceuticals, pharmaceuticals, and blood-based biomarkers for aging.
Contact: Sarah Thomas
Business Development Manager
Myto Health LLC